三子方对大肠腺瘤内镜治疗患者术后疗效、免疫功能及生活质量的影响  

Effect of Sanzi Prescription(三子方)on Postoperative Efficacy,Immune Function and Quality of Life of Patients Treated by Endoscopy for Colorectal Adenoma

作　　者：陈允旺[1] 田耀洲[2] 林琳[2] 魏引廷[1] 张卿 CHEN Yunwang;TIAN Yaozhou;LIN Lin;WEI Yinting;ZHANG Qing(Lianyungang Hospital of Traditional Chinese Medicine,Lianyungang 222000,Jiangsu,China;Jiangsu Integrated Traditional Chinese and Western Medicine Hospital,Nanjing 210000,Jiangsu,China)

机构地区：[1]连云港市中医院,江苏连云港222000 [2]江苏省中西医结合医院,江苏南京210000

出　　处：《辽宁中医杂志》2023年第9期119-122,共4页Liaoning Journal of Traditional Chinese Medicine

基　　金：江苏省中医药管理局科技项目(JD2019SZXYB15,JD2019SZXZD02)。

摘　　要：目的观察三子方对大肠腺瘤内镜治疗患者术后疗效、免疫功能以及生活质量的影响。方法研究纳入大肠腺瘤内镜治疗患者合计67例(2020年1月—2021年6月收治),将患者以随机数字表法分为三子方模拟剂组(33例)与三子方组(34例),三子方组患者内镜治疗后给予三子方治疗,三子方模拟剂组患者内镜治疗后给予其模拟剂,均治疗12周。数据观察:两组患者临床疗效、治疗前后中医证候积分(腹胀、腹痛、里急后重、大便稀溏、食少等)变化、并发症与不良反应情况、治疗前后CD_(4)^(+)、CD_(8)^(+)等免疫指标变化、治疗后生活质量提升率,随访1年,比较各组复发率及癌变率。结果三子方组治疗总有效率比三子方模拟剂组高[94.12%(32/34)vs 75.76%(25/33)](P<0.05);治疗前,各组患者中医证候积分(腹胀、腹痛、里急后重、大便稀溏、食少等)、CD_(4)^(+)、CD_(8)^(+)等免疫指标比较差异无统计学意义(P>0.05),治疗后各组患者中医证候积分(腹胀、腹痛、里急后重、大便稀溏、食少等)、CD_(4)^(+)、CD_(8)^(+)等免疫指标均改善,三子方组治疗后中医证候积分(腹胀、腹痛、里急后重、大便稀溏、食少等)、CD_(4)^(+)、CD_(8)^(+)等免疫指标均优于三子方模拟剂组,差异有统计学意义(P<0.05);三子方组患者治疗后生活质量提升率高于三子方模拟剂组[97.06%(33/34)vs 75.76%(25/33)](P<0.05);两组均未见并发症与不良反应;三子方组复发率低于三子方模拟剂组[5.88%(2/34)vs 24.24%(8/33)](P<0.05);两组均未见癌变(P>0.05)。结论三子方可提升大肠腺瘤内镜治疗患者临床疗效,改善患者临床症状,提升患者免疫能力与生活质量,降低患者复发率,可一定程度意义癌变,值得应用。Objective To observe the effect of Sanzi Prescription(三子方)on postoperative efficacy,immune function and quality of life of patients treated with enteric adenoma.Methods A total of 67 patients with enteric adenoma undergoing endoscopic treatment were included in the study(admitted from January 2020 to June 2021).The patients were randomly divided into Sanzi Prescription simulator group(33 cases)and Sanzi Prescription group(34 cases)using a random number table method.The Sanzi Prescription group received Sanzi Prescription after endoscopic treatment,while the Sanzi Prescription simulator group received the simulator agent after endoscopic treatment,all of which were treated for 12 weeks.The clinical efficacy of the two groupschanges in TCM syndrome scores(abdominal distention,abdominal pain,rectal tenesmus,loose stool,lack of food,etc.)before and after treatment,complications and adverse reactions,changes in CD_(4)^(+)and CD_(8)^(+)and other immune indicators before and after treatment,and the improvement rate of quality of life after treatment of two groups were compared.The patients were followed up for one year to compare the recurrence rate and canceration rate of each group.Results The total effective rate of Sanzi Prescription group was higher than that of Sanzi Prescription simulator group[94.12%(32/34)vs 75.76%(25/33)](P<0.05).Before treatment,the scores of TCM syndromes(abdominal distension and discomfort,abdominal pain,tenesmus and afterweight,loose stools,lack of food,etc.),CD_(4)^(+),CD_(8)^(+)and other immune indexes were not significant(P>0.05).After treatment,TCM syndrome scores(abdominal distension,abdominal pain,tenesmus,loose stool,lack of food,etc.),CD_(4)^(+),CD_(8)^(+)and other immune indexes were improved in each group.After treatment,TCM syndrome score(abdominal distension,abdominal pain,tenesmus,loose stool,less food,etc.),CD_(4)^(+),CD_(8)^(+)and other immune indexes in Sanzi Prescription group were better than Sanzi Prescription simulator group(P<0.05).The improvement rate of quality

关 键 词：大肠腺瘤 内镜 手术 三子方 三子方模拟剂 疗效 免疫功能 

分 类 号：R735.34[医药卫生—肿瘤]